Literature DB >> 34258725

The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent.

David Miller1, Benedic Ippolito2, Inmaculada Hernandez3, Benjamin Davies4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34258725      PMCID： PMC8858345          DOI： 10.1007/s11606-021-07000-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  3 in total

1.  Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.

Authors:  Tahir Amin; Aaron S Kesselheim
Journal:  Health Aff (Millwood)       Date:  2012-10       Impact factor: 6.301

2.  FOUR FACTS CONCERNING COMPETITION IN U.S. GENERIC PRESCRIPTION DRUG MARKETS.

Authors:  Rena M Conti; Ernst R Berndt
Journal:  Int J Econ Bus       Date:  2019-09-05

3.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.